Cyient DLM Q1: consolidated PAT more than doubles YoY to ₹16.3 Cr, revenue up 34%
PAT +118.2% YoY · revenue +34.25% · margins expanding
₹373.8 Cr
+34.25% YoY
₹16.29 Cr
+118.2% YoY
4.35%
+1.7pp YoY
₹2.05
Cyient DLM reported consolidated revenue of ₹373.8 Cr for Q1 FY27, up 34.3% YoY (and 1.3% QoQ), with net profit of ₹16.3 Cr — up 118% from ₹7.5 Cr a year ago. The profit surge is entirely operating-driven: PBT more than doubled YoY to ₹22.2 Cr from ₹10.1 Cr even as other income collapsed to ₹0.27 Cr (from ₹4.18 Cr a year earlier), so none of the improvement leans on non-operating income. EBITDA margin expanded to ~10.5% from 9.0% YoY on operating leverage as volumes scaled.
Q1 FY-2027 vs prior quarters
Sequentially the picture is softer — PAT fell 27% from ₹22.4 Cr in Q4 FY26 and NPM eased to 4.4% from 6.0%, with EBITDA margin down from 11.7% to 10.5%. But Q4 is seasonally the strongest quarter and carried ₹5.1 Cr of other income (including earnout fair-value gains) that did not recur; the QoQ dip is seasonality plus normalization of other income rather than operating deterioration. Standalone PAT (₹16.7 Cr on ₹282.9 Cr revenue) tracks consolidated closely — the US subsidiaries (Cyient DLM Inc., Altek) add topline but are roughly profit-neutral this quarter.
The stock went into the print at ₹623, up 31.5% over the past month of trading.
Management withholds specific quantitative revenue guidance for FY27 but confidently projects a strong year with a return to growth, driven by a record-high order book and a sales pipeline of approximately $0.5 billion. The company expects to sustain double-digit EBITDA margins, with potential for further improvement f
— This quarter: met
Against its own framing, the print delivers: on the Q4 concall management withheld quantitative revenue guidance but projected a return to growth and sustained double-digit EBITDA margins off a record order book (₹2,416.6 Cr, ~50% earmarked for short-to-medium-term execution) — this quarter shows both, +34% YoY growth at a 10.5% EBITDA margin. No brokerage consensus is on record for a company this size, so the result cannot be scored against street. The quarter also carried management churn — Ramakanth Alapati appointed President & Chief Strategy Officer in May, and director Y. Muralidhar's tenure ended in July — while a ₹16.9 Cr fair-value decline on an IP-communications investment sits in Q4's OCI, below the profit line, with no bearing on reported earnings.
What to watch
W1
Conversion of the ₹2,416.6 Cr order book — ~50% is short-to-medium execution, so H2 revenue ramp is the checkpoint on management's return-to-growth claim
W2
Sustainability of the double-digit EBITDA margin (10.5% now) as volumes rise — management guided to operating-leverage-led improvement
W3
Whether QoQ profit rebuilds toward the ₹22.4 Cr Q4 level once seasonality and one-off other income normalize
Source in ₹ Millions, converted to Crore (÷10). No P&L exceptional items. Other income unusually low this quarter (₹0.27 Cr consol vs ₹5.13 Cr QoQ, ₹4.18 Cr YoY) — profit jump is fully operational. A ₹16.9 Cr fair-value decline on an IP-comms investment was booked in OCI in Q4-FY26, below PAT, not in P&L. Standalone vs consolidated PAT near-identical (<3% divergence).
Record Order Book, But Sequential Profit Collapsed — Execution Questions Persist
Cyient DLM's Q1 delivered a record ₹2,598 crore order book and dazzled the street with 34% YoY revenue growth. But scroll to the sequel — profit fell 27% quarter-on-quarter. The harder question: can management convert that backlog into sequential momentum while unproven new segments ramp?
Cyient DLM's Q1 result sparked a 12% rally on day one. The headline is bulletproof: a record ₹2,598 crore order book, 34% revenue growth year-on-year, 118% profit growth year-on-year, and a robust 1.5x book-to-bill ratio. The street bought the narrative of strong demand and aerospace/defence dominance. But scroll down to the quarter-on-quarter numbers, and the story flips — profit crashed 27% in a single quarter while revenue inched up just 1.3%. That gap between the order-book strength and sequential execution failure is the quarter's defining tension.
Where the YoY growth came from
+40%
42% of Q1 revenue; largest segment
+90%
32% of Q1 revenue; diversification driver
+21%
48% of product mix; sustained strength
Flat
16% of revenue; seasonal headwind cited
The YoY story is real. Aerospace and industrial posted exceptional growth, new logos were onboarded (30% of Q1 order intake from customers added in recent quarters), and the order backlog is the highest in company history. This is not a mirage. But the quarter-on-quarter reality is harder to square: if the order book is at record ₹2,598 crore with 1.5x book-to-bill, why did profit fall 27% sequentially and revenue rise only 1.3%?
The sequential collapse
Management's explanation centers on two headwinds. First, organizational investments — the company hired a new Chief Strategy & Growth Officer and onboarded sales directors for AI/robotics, costs that hit Q1 directly. Second, B2S (build-to-spec) procurement spending, as the company builds prototype electronics for Honeywell's aerospace vehicle and SkyDrive's autonomous vehicle. These are strategic, forward-looking investments. But the math is sobering: gross margin compressed, and PAT fell from approximately ₹22.5 crore in Q4 to ₹16.3 crore in Q1.
Investments are where we have already budgeted and we already kept it because that is the one thing probably which is just driving up our gross margins slightly lower.
This is not an earnings quality red flag — management flagged the investments openly and acknowledged the margin hit. But it does raise a credibility question: how many quarters of this dynamic should investors expect before new segments start contributing revenue? The company positioned AI/robotics as a multi-year expand phase (FY27–FY29) targeting 11–13% EBITDA margins. If the investments continue but proof points (customer wins, revenue contribution) don't materialize in the next 2–3 quarters, the narrative breaks.
Management's claims: graded
"Record highest order book in company history" — ₹2,598 Cr confirmed; up ₹183 Cr quarter-on-quarter
"Robust 1.5x book-to-bill maintained for FY27" — Confirmed in guidance; no lumpy orders
"Double-digit EBITDA margins sustained for four consecutive quarters" — 10.5% in Q1; 4-quarter run confirmed
"Revenue growth momentum driven by order book" — 34.3% YoY holds up, but 1.3% QoQ is weak conversion
"AI/robotics entry will drive margins to 11–13% by FY29" — Sales directors onboarded Q1; no revenue yet; timing TBD
"Profitable growth continues as primary objective" — YoY PAT +118%, but QoQ -27.4%; mixed execution
What changed
New leadership and capability expansion signal a strategic pivot. Rama Alapati (Chief Strategy & Growth Officer) and new sales directors for AI/robotics were onboarded in Q1 — a meaningful hiring acceleration that wasn't present in prior quarters. The build-to-spec lab was expanded 150% (from 6,000 to 15,000 sq ft), positioning Cyient DLM to serve Honeywell and SkyDrive on electronics design and prototype builds. Two new logos were added across industrial and automotive segments. These moves are consistent with the 'Expand Phase' strategy (FY27–FY29) that management outlined — but they also explain the margin pressure on Q1. The company is making bets; Q1 is showing the cost, not yet the payoff.
Earnings quality: where to worry
Bull and bear ledgers
Record order book (₹2,598 Cr, 1.5x B2B) is the highest in company history; de-risks near-term revenue
Aerospace moat is real: Honeywell major ramp-up (18-month production cycle underway); Thales 'extraordinary growth' expected; Safran ongoing
Industrial +90% YoY and 32% of revenue; diversification away from aerospace concentration
Strategic hiring (CSGO, sales directors) and B2S lab expansion show intentional capability building, not reactionary
YoY delivery: revenue +34.3%, PAT +118%; company met prior FY26 guidance on order book and margins
Sequential PAT -27.4% QoQ despite revenue +1.3% QoQ; order-book strength did not convert to sequential momentum
Organizational investments pressuring margins; unclear how many quarters of cost before new segments deliver revenue
AI/robotics strategy unproven: sales directors onboard Q1, no Q1 revenue, no concrete customer or timeline disclosed
Working capital deteriorating: WC days 161 (up 16 QoQ); inventory 162 days; negative FCF dependent on growth narrative holding
Valuation extended: RSI 74 (overbought), stock -9.4% from all-time high but 23% above SMA200; FII exited to 0.79% from 2.48% a year ago
How the street is positioned
The post-result rally of 12% on day one held through the week, with strong delivery (24.8% of volume traded). The street clearly loved the order-book headline and YoY growth. But ownership data tells a different story. Foreign institutional investors (FII) have exited aggressively: from 2.48% in Q1 FY26 to just 0.79% in Q4 FY26 — a wholesale exit during the rally. Domestic institutional investors (DII) remain stable at 26–29%, and promoters hold steady at 52%. The asymmetry is telling: FII took profits into the rally, suggesting skepticism on whether new-segment execution can justify the multiple. At ₹665.1, the stock trades 23% above its 200-day average, 38% above its 50-day average, and is -9.4% from its all-time high. RSI of 74 screams overbought. The rally priced in the order book and near-term upside; reversal risk is tangible.
Ranked risks
New-segment execution failure (AI/robotics/semicon)
High11–13% EBITDA margin roadmap (FY27–FY29) hinges entirely on these segments ramping. Sales directors onboard Q1 but no products, customers, or concrete timelines yet. 2–3 quarter visibility lag is critical; if no proof emerges by Q3 FY27, the narrative collapses and multiples compress sharply.
Working capital deterioration and negative FCF
MediumInventory 162 days (up 9 QoQ), advances 15 days (down 3 QoQ), net WC 161 days (up 16 QoQ). Management says this is growth investment, but if order-book conversion slows or new segments don't ramp, this inventory becomes a cash drag and depresses ROE.
Sequential momentum doesn't recover
MediumIf Q2 shows another sequential decline (PAT negative QoQ again), the narrative that investments are 'leading indicators' breaks. Multiple compression and re-rating downward become real risks. The ₹2,598 Cr order book is only credible if converted to sequential revenue.
MedTech segment stays flat
Medium16% of revenue is significant. Flat YoY growth despite broad-based strength (aerospace +40%, industrial +90%) suggests sector headwinds. If MedTech remains stalled for 2+ quarters, diversification thesis weakens and valuation support erodes.
Geopolitical supply-chain disruption
MediumWest Asia crisis causing logistics delays and cost inflation. Strategic inventory mitigated Q1 impact, but sustainability is uncertain. Israeli orders (pending approvals) add complexity. Escalation or persistence of crisis could force higher input costs and margin compression.
The debate
What to watch next
1 · Q2 sequential momentum (next 6–8 weeks)
Did the ₹2,598 Cr order book convert to sequential revenue growth in Q2? If revenue stays flat-to-down quarter-on-quarter again, the order-book narrative breaks. The street paid up for conversion; delivery is non-negotiable.
2 · New-segment clarity and customer wins (Oct–Dec 2026)
AI/robotics strategy updates due in 2–3 quarters. Watch for concrete proof: named customers, product milestones, realistic timelines. 'Sales directors onboard' is table stakes; proof points are the bar.
3 · Working capital normalization
Inventory 162 days, advances 15 days, net WC 161 days are elevated. Watch if these normalize as growth moderates or if negative FCF persists into H2 FY27. Persistent negative FCF erodes the thesis.
4 · B2S revenue ramp timing
Management guides meaningful revenue 1–18 months away (i.e., by Dec 2027). Honeywell EAV and SkyDrive Japan are in engineering design phase. Watch for production ramp visibility and margin contribution estimates in Q3–Q4 FY27 calls.
Cyient DLM enters FY27 with the strongest order book in its history and a proven aerospace/defence moat. That's the foundation. But Q1's sequential profit collapse — despite record backlog — raises a hard question: can management execute the ramp-up while bootstrapping unproven new segments? The ₹2,598 crore backlog is real and de-risks revenue. But until new segments deliver proof and sequential momentum returns, this is a steady execution story, not a step-change.
The single number to track: sequential PAT growth in Q2. If the order book converts to sequential revenue and margin expansion, the bull case holds and the ₹665 price is defensible. If not, a sharp correction awaits. FII's wholesale exit (to 0.79% from 2.48%) already prices in skepticism; retail and DII euphoria won't sustain the rally on promises alone.
Record order book & strong growth, but sequential momentum halts
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met prior FY26 guidance on record order book, double-digit margins, >1.0 book-to-bill. Weak sequential execution (PAT -27.4%) and vague new-segment timelines temper confidence.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong order book (₹2,598 Cr, 1.5x book-to-bill) and YoY growth (revenue +34.3%, PAT +118%) signal healthy demand and execution. However, sequential momentum broke (PAT -27.4% QoQ, revenue +1.3%), MedTech flat, and negative FCF driven by inventory build raise near-term concerns. Multi-phase margin roadmap (11-18% by FY30) hinges on unproven AI/robotics ramp, which management positions as 2-3 quarter visibility. Aerospace moat (Honeywell, Thales) and strong order intake warrant patience, but execution on new segments is key risk to validate the 11-13% expand-phase target.
₹373.8 Cr
Revenue · +34.3% YoY₹16.3 Cr
Reported PAT · +118.2% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Record highest order book in company history
MET₹2,598 Cr order book, ₹25.989 billion confirmed
Robust book-to-bill ratio of 1.5x
MET1.5x book-to-bill confirmed; order intake ₹551.9 Cr
Sustained double-digit EBITDA margins for four consecutive quarters
MET10.5% in Q1 FY27 (147 bps expansion YoY), confirmed 4-quarter run
Revenue growth momentum driven by order book
OVERSTATED34.3% YoY, but QoQ only +1.3% despite record order book
New logos added in Q1 broadening revenue base
MET2 logos added across industrial/automotive, 30% of Q1 intake from new customers (4-6 quarter vintage)
AI/robotics entry driving margin expansion to 11-13% by FY29
UnverifiedSales directors just onboarded Q1, no Q1 revenue yet, timeline TBD in next 2-3 quarters
Profitable growth continues to be primary objective
MixedPAT margin 4.4%, but QoQ PAT -27.4% despite revenue +1.3%
Earnings quality
What changed since the last call
Order book highest ever
Upgrade₹2,598 Cr vs ₹2,130 Cr in Q4 FY26 (₹183 Cr QoQ increase). Book-to-bill 1.5x vs 1.4x expected, reinforcing demand confidence.
Sequential PAT reversed
DowngradeQ1 PAT ₹163M (-27.4% QoQ from ~₹225M in Q4). Gross margin compression and organizational investment costs drove decline despite revenue growth.
MedTech growth stalled
Downgrade16% of revenue, flat YoY growth vs prior quarters' expansion. Seasonal customer impact cited, but no visibility to recovery.
Strategic hiring acceleration
UpgradeChief Strategy & Growth Officer (Rama Alapati) onboarded; AI/robotics sales directors added. Enhances go-to-market for new segments (FY27-29 expand phase).
Capex intensity unchanged
Neutral1.75-2x revenue run-rate; no incremental capex needed for AI/robotics expansion. Existing facilities sufficient for execution.
The Q&A
Analyst Q&A was substantive and probing. Queries on AI/robotics timelines, semicon capital equipment ramp, and FY27 revenue guidance were direct; management held line on non-disclosure of specific targets but provided operational color (sales directors onboard, 2-3 quarter visibility). Push on sequential margin decline acknowledged but justified via mix/investment. No signs of evasion on order book sustainability (1.5x reaffirmed for full year) or new-logo scaling. Credible but disciplined tone.
West Asia crisis impact — Gaurav Shukla, Finvestors
AnsweredCrisis still present with logistics delays and cost increases observed. Strategic inventory build and execution planning mitigated Q1 impact. Israeli customer momentum continues; expect momentum in Q2. No material disruption seen yet.
AI data centre entry — Vipraw Srivastava, PhillipCapital
PartialEarly stage. Sales directors onboarded this quarter. Will provide updates in next 1-2 quarters on focus areas and momentum. No concrete customer or timeline disclosed yet.
Semicon equipment timeline — Vipraw Srivastava, PhillipCapital
AnsweredExpected 6-12 months for revenue growth impact. Existing capital equipment customers showing robust growth. Continued investment in this area.
FY27-29 CAGR guidance — Deepak Krishnan, Kotak Institutional Equities
DodgedNo specific revenue guidance given. Internal plans exist for expand phase mix and CAGR, but not disclosed publicly. Updates once new customers secured (2-3 quarters).
B2S margin uplift — Praveen Sahay, PL Capital
AnsweredMeaningful revenue in next 1-18 months. B2S will add 250-300 bps EBITDA margin upside to consolidated profile vs core EMS business.
Working capital normalization — Praveen Sahay, PL Capital
AnsweredDriven by higher inventory and lower customer advances to support growth. Justified as leading indicator for future revenue. Will normalize once growth rate moderates and inventory controlled.
Order inflow sustainability — Deepak, Unifi Capital
AnsweredNo lumpy orders; 70% from existing customers, 30% from new logos onboarded last 4-6 quarters. Substantial opportunity still with both cohorts. 1.5x book-to-bill to be maintained for full year.
Honeywell aerospace ramp — Adityapal, MSA Capital Partners
AnsweredHoneywell: Major order won years back now entering initial production ramp. Expect significant growth coming 18 months. Strong engagement at multiple levels. Thales: Extraordinary growth expected this year. Multiple major OEM/Tier-1 accounts active.
New segment margin assumptions — Santhosh Seshadri, Avendus Spark
PartialCurrent expansion from filling hopper and operating leverage. Future upside from new sectors (AI, robotics, semicon capital equipment) to come in FY27-29, targeting 11-13% EBITDA. No inherent cost advantage; high-profile margin business model.
Forex impact on EMS margins — Deepak Krishnan, Kotak Institutional Equities
AnsweredRupee appreciated in Q1 final month; balance sheet exposed to export/import FX. Net impact visible on balance sheet. Standard exposure management.
Guidance
Similar momentum expected Q2 FY27; no quantitative target
MediumManagement expects order intake/momentum to continue at similar levels. 1.5x book-to-bill to be maintained for full year. No absolute revenue target or CAGR disclosed.
Double-digit EBITDA margins sustained; current 10.5%
HighFour consecutive quarters of double-digit run achieved. Management committed to margin expansion via operating leverage and new-segment contribution (FY27-29 target: 11-13%).
Expand phase (FY27-29): 11-13% EBITDA margins via AI/robotics/semicon
LowAspirational roadmap lacking quantified revenue ramp or concrete mechanisms. Timeline for meaningful new-segment revenue 2-3 quarters out.
Transform phase (FY30+): 13-18% EBITDA via B2S moat
LowMulti-year aspiration hinging on B2S product scaling and platform IP ownership. No P&L evidence yet; B2S meaningful revenue 1-18 months away.
No incremental capex for new segments; 1.75-2x revenue run-rate maintained
HighExisting facilities and capabilities sufficient for AI/robotics/semicon expansion. Regular annual capex continues; no transformative investment needed.
Risks the call surfaced
New segment execution
HighAI data center and robotics positioned as 11-13% margin drivers by FY29, but only sales directors onboarded Q1. No Q1 revenue, customer proof, or product clarity. 2-3 quarter visibility lag critical risk to margin roadmap.
Working capital & cash flow
MediumInventory days 162 (up 9 QoQ); customer advances 15 days (down 3 QoQ); net WC days 161 (up 16 QoQ). Operating cash flow negative. Management justified as growth investment but tail risk if revenue conversion slows.
MedTech segment stall
MediumMedTech 16% of Q1 revenue, flat YoY, attributed to seasonal customer impact. No acceleration visible despite overall order book momentum. If sector slowdown persists, diversification thesis weakens and margin expansion dependent on aerospace/industrial leverage.
Sequential margin compression
MediumQ1 PAT ₹163M fell sharply QoQ (from ~₹225M Q4) as gross margin compressed due to organizational investments and procurement for B2S. Risk that margin expansion stalls if sequential execution doesn't improve.
Geopolitical supply chain disruption
MediumWest Asia crisis still ongoing; logistics delays and cost increases observed in Q1. Strategic inventory buildup and alternative sourcing mitigated impact in Q1, but sustainability risk if crisis persists or escalates. Israeli orders still in motion but with approvals delays.
Management
Score 7/10. Clear, articulate, and structured. Rajendra Velagapudi presented 3-phase strategy (Strengthen/Expand/Transform) with crisp messaging. Management transparent on constraints (won't disclose new-segment revenue mix, CAGR) but provided operational color where possible. Krishna Bodanapu provided confidence-building opening and closing. No evasion on core facts; dodged specific growth guidance deliberately. Strong track record on prior FY26 guidance: record order book achieved, double-digit margins sustained, book-to-bill >1.0 delivered, new logos added. Q1 delivered revenue +34.3% YoY and PAT +118.2% YoY. However, QoQ PAT -27.4% suggests near-term momentum question. Aerospace (+40%), industrial (+90%) performing; MedTech flat. B2S early stage.
1 · Sep 2026
Honeywell Aerospace ramp-up expected; 18-month production cycle from prior order
2 · Q2 FY27
Management expects similar momentum in order intake and revenue; 1.5x book-to-bill sustained
3 · Oct-Dec 2026
AI/robotics strategy clarification; sales directors to report product/customer focus and timing
Aerospace moat (Honeywell, Thales) and strong order intake warrant patience, but execution on new segments is key risk to validate the 11-13% expand-phase target.